Work With Us
Contact Us
Work With Us
Contact Us
Search
Search
Close this search box.
Home
About Us
Our Mission and Vision
Meet the Team
Board of Directors
Scientific Advisory Board
Investors
Our Science
About Macrocycles
Introducing MXMO
TM
Our Pipeline
Publications
What’s New
Press Releases
Events
Menu
Home
About Us
Our Mission and Vision
Meet the Team
Board of Directors
Scientific Advisory Board
Investors
Our Science
About Macrocycles
Introducing MXMO
TM
Our Pipeline
Publications
What’s New
Press Releases
Events
Press
Releases
News
Latest
press releases
Circle Pharma’s First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor, CID-078, Preclinical Data Highlighted at the 36th EORTC-NCI-AACR Symposium
October 23, 2024
Press Releases
Circle Pharma announces first patients dosed in Phase 1 clinical trial of first-in-class oral Cyclin A/B RxL inhibitor
CID-078 for advanced solid tumors
October 15, 2024
Press Releases
Boehringer Ingelheim and Circle Pharma announce new research collaboration to develop a novel precision cancer treatment
October 9, 2024
Press Releases
Circle Pharma expands leadership team to drive the development of its pipeline of oral macrocycle therapies
September 16, 2024
Press Releases
Circle Pharma announces preclinical data poster presentation of CID-078, a first-and-only-in-class Cyclin A/B RxL inhibitor at the 2024 World Conference on Lung Cancer
September 9, 2024
Press Releases
Circle Pharma Closes $90 Million Series D Financing to Advance Innovative Oral Macrocycle Therapies
September 3, 2024
Press Releases
LOAD MORE
Sign up to stay informed
SUBSCRIBE
Subscribe to our News Alerts
By checking the box and pressing the subscribe button , I acknowledge and accept Circle Pharma’s
Privacy Policy
and
Terms of Service.
Subscribe
